Results 91 to 100 of about 7,648 (236)

Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma [PDF]

, 2014
High-grade Brainstem Glioma (BSG), also known as Diffuse Intrinsic Pontine Glioma (DIPG), is an incurable pediatric brain cancer. Increasing evidence supports the existence of regional differences in gliomagenesis such that BSG is considered a distinct ...
Baker, Suzanne J., Barton, Kelly L., Becher, Oren J., Chung, Alexander, Conway, Simon J., Corcoran, David L., Diaz, Alexander K., Misuraca, Katherine L.   +7 more
core   +3 more sources

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Reduced GS domain serine/threonine requirements of Fibrodysplasia Ossificans Progressiva mutant type I BMP receptor ACVR1 in the zebrafish

bioRxiv, 2022
Fibrodysplasia ossificans progressiva (FOP) is a rare human genetic condition characterized by altered skeletal development and extra-skeletal bone formation.
Robyn S. Allen, W. D. Jones, Maya Hale, Bailey Warder, E. Shore, M. Mullins   +5 more
semanticscholar   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source

Development of the SIOPE DIPG network, registry and imaging repository : a collaborative effort to optimize research into a rare and lethal disease [PDF]

, 2017
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival.
Bailey, S, Barkhof, F, Baugh, J, Biassoni, V, Bison, B, Calmon, R, Cannarozzo, A, Castel, D, Chaney, B, Colditz, N, Cruz, O, Damen-Korbijn, CM, De Jongh, D, De Wolf, R, Deak, L, Emmerik, J, Entz-Werle, N, Fouladi, M, Gandola, L, Garami, M, Gerber, N, Gielen, GH, Gil-da-Costa, MJ, Giraud, G, Grill, J, Grundy, R, Hargrave, DR, Hauser, P, Hayden, T, Hoffmann, M, Holm, S, Hulleman, E, Jacobs, S, Jadrijevic-Cvrlje, F, Janssens, GO, Jones, C, Jones, DT, Kaspers, GJ, Kattamis, A, Kebudi, R, Kitanovski, L, Kivivuori, SM, Kramm, CM, Leblond, P, Lieverst, JA, Lopez-Aguilar, E, Massimino, M, members of the SIOPE DIPG Network, ., Morales La Madrid, A, Noltes, J, Nysom, K, Pears, J, Pentikainen, V, Perek-Polnik, M, Rutkauskiene, G, Sanchez Aliaga, E, Shats, L, Slavc, I, Sturm, D, Sumerauer, D, Thorarinsdottir, HK, Torsvik, IK, Van Dijk, J, Van Gool, S, van Vuurden, DG, Vandertop, WP, Varlet, P, Veldhuijzen van Zanten, SE, von Bueren, AO, Warmuth-Metz, M, Zapata-Tarres, M, Zheludkova, O   +71 more
core   +5 more sources

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G A mutation

The Pan African Medical Journal, 2015
Fibrodysplasia ossificans progressiva is a rare autosomal dominantly inherited disorder of connective tissue caused by mutations in the gene encoding for ACVR1/ALK2, a bone morphogenetic protein type I receptor.
Mohammed Saleh, Joost Commandeur, Renata Bocciardi, Grace Kinabo, Ben Hamel   +4 more
doaj   +1 more source

The prognostic value and potential immunotherapeutic efficacy of ACVR1 in treating gastric cancer

Journal of Gastrointestinal Oncology
Background The discovery of biomarkers has facilitated the treatment of cancer. At present, the relationship between activin A receptor type-1 (ACVR1) and gastric cancer is gradually discovered.
Hui Zhang, Ruiqi Liu, Yanrong Chen, Ruicong Ma, Qiang Xue, Arvind Sahu, Xiaodi Yan, Hongmei Gu   +7 more
semanticscholar   +1 more source

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice

bioRxiv, 2021
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by progressive and catastrophic heterotopic ossification (HO) of skeletal muscle and associated soft tissues.
John B. Lees-Shepard, Sean J. Stoessel, J. Chandler, K. Bouchard, Patricia Bento, Lorraine N. Apuzzo, Parvathi M. Devarakonda, Jeffrey W. Hunter, D. Goldhamer   +8 more
semanticscholar   +1 more source

Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib. Methods The RUX‐MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment‐emergent ...
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, Mario Tiribelli, Erika Morsia, Mirko Farina, Giulia Benevolo, Eloise Beggiato, Bruno Martino, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Alessandra Iurlo, Alessandro Isidori, Alessandra Dedola, Emilia Scalzulli, Andrea Duminuco, Daniele Cattaneo, Roberto M. Lemoli, Costanza Bosi, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Chiara Sartor, Florian H. Heidel, Massimo Breccia, Filippo Branzanti, Giuseppe A. Palumbo, Massimiliano Bonifacio, Elena M. Elli   +31 more
wiley   +1 more source